Bleakley Financial Group LLC Has $1.77 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Bleakley Financial Group LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,881 shares of the biopharmaceutical company’s stock after buying an additional 1,869 shares during the quarter. Bleakley Financial Group LLC’s holdings in Gilead Sciences were worth $1,773,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Cetera Investment Advisers grew its stake in Gilead Sciences by 9.2% in the 1st quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock valued at $3,446,000 after buying an additional 4,877 shares during the last quarter. Baird Financial Group Inc. grew its stake in Gilead Sciences by 3.9% in the 1st quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after buying an additional 16,643 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Gilead Sciences by 44.3% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 2,654 shares during the last quarter. Donaldson Capital Management LLC grew its stake in Gilead Sciences by 12.5% in the 1st quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 641 shares during the last quarter. Finally, Ergoteles LLC acquired a new position in Gilead Sciences in the 1st quarter valued at $2,304,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Royal Bank of Canada reduced their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Wells Fargo & Company reduced their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Barclays reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. Finally, Oppenheimer reduced their price target on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $85.36.

Gilead Sciences Trading Down 2.6 %

Shares of GILD stock opened at $68.12 on Thursday. Gilead Sciences, Inc. has a 12-month low of $68.06 and a 12-month high of $87.86. The company has a market capitalization of $84.81 billion, a P/E ratio of 15.14, a P/E/G ratio of 0.88 and a beta of 0.19. The firm has a 50-day moving average price of $73.16 and a 200 day moving average price of $76.92. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the business earned $1.67 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.52%. The ex-dividend date was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the sale, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the sale, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,000 shares of company stock worth $721,180. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.